Company Long-Term Loans and Borrowings: Regeneron Corp (REGN)

The high profitability of the biotech behemoth Regeneron Pharmaceuticals (REGN) is based on the treatment of ophthalmological and immune pathologies, which is confirmed by the company's long-term debt dynamics. The value of 2.03 is recorded as the baseline value. Facilities in the US and Ireland ensure the production of key drugs, while the introduction of Eylea HD and the development of oncology stimulate growth despite pressure from biosimilars.

Long-term debt reflects the aggregate of obligations with maturities exceeding one year, determining the issuer's long-term credit burden. Analyzing the time series of a business's long-term borrowed capital allows for the identification of hidden borrowing spikes before they are reflected in quarterly reports. This distinguishes systemic financial strategy from one-off credit operations. For Regeneron Pharmaceuticals (REGN), monitoring this metric confirms the ability to maintain monopoly profits from patents without excessive debt pressure.